Outcomes of the European Federation of Pharmaceutical Industries and Associations Oligonucleotide Working Group Survey on Nonclinical Practices and Regulatory Expectations for Therapeutic Oligonucleotide Safety Assessment
Yann Tessier(Roche (Switzerland)), Laurence O. Whiteley(Unknown), Joel D. Parry(Age UK), Jonathan G. Moggs(Novartis (Switzerland)), Lauren Mihalcik(Bioanalytica (Switzerland)), Chidozie J. Amuzie(Johnson & Johnson (United States)), William E. Achanzar(Bristol-Myers Squibb (Germany)), Patrik Andersson(AstraZeneca (South Korea))
Cited by 14
Related Papers
Doxorubicin In Vivo Rapidly Alters Expression and Translation of Myocardial Electron Transport Chain Genes, Leads to ATP Loss and Caspase 3 Activation
|PLoS ONE|2010|127
Molecular mechanisms of IL-33–mediated stromal interactions in cancer metastasis
|JCI Insight|2018|118
<i>In silico</i>and<i>in vitro</i>evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization
|Nucleic Acids Research|2015|109
Assessing unintended hybridization-induced biological effects of oligonucleotides
|Nature Biotechnology|2012|108
Challenges for inhaled drug discovery and development: Induced alveolar macrophage responses
|Advanced Drug Delivery Reviews|2014|91